Memorial Sloan Kettering Cancer Center: ASCO 2020 - Targeted Treatment Shows Promise in Non-Small Cell Lung Cancer
May 30, 2020
May 30, 2020
NEW YORK, May 30 -- The Memorial Sloan Kettering Cancer Center issued the following news release:
Researchers at Memorial Sloan Kettering Cancer Center (MSK) published updated data in the New England Journal of Medicine from the ongoing, single-arm phase II VISION study evaluating tepotinib as a single agent in patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations. This data is also featured as part of the American Society of Clini . . .
Researchers at Memorial Sloan Kettering Cancer Center (MSK) published updated data in the New England Journal of Medicine from the ongoing, single-arm phase II VISION study evaluating tepotinib as a single agent in patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations. This data is also featured as part of the American Society of Clini . . .